These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15576952)

  • 1. [Target range of PTH in uremia].
    Tahara H; Tabata T
    Clin Calcium; 2004 Jan; 14(1):39-44. PubMed ID: 15576952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [PTH assay: new and future].
    Nakanishi S; Fukagawa M
    Clin Calcium; 2001 Aug; 11(8):1019-23. PubMed ID: 15775609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating 1-84 PTH and large C-terminal PTH fragment levels in uremia.
    Kazama JJ; Omori T; Ei I; Ei K; Oda M; Maruyama H; Narita I; Gejyo F; Shigematsu T; Fukagawa M
    Clin Exp Nephrol; 2003 Jun; 7(2):144-9. PubMed ID: 14586733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel mechanism for skeletal resistance in uremia.
    Slatopolsky E; Finch J; Clay P; Martin D; Sicard G; Singer G; Gao P; Cantor T; Dusso A
    Kidney Int; 2000 Aug; 58(2):753-61. PubMed ID: 10916099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia.
    Quarles LD; Lobaugh B; Murphy G
    J Clin Endocrinol Metab; 1992 Jul; 75(1):145-50. PubMed ID: 1619003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PTH measurement: where do we stand?].
    Marangella M
    G Ital Nefrol; 2009; 26(5):600-7. PubMed ID: 19802805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skeletal resistance to parathyroid hormone as a background abnormality in uremia.
    Fukagawa M; Iwasaki Y; Kazama JJ
    Nephrology (Carlton); 2003 Oct; 8 Suppl():S50-2. PubMed ID: 15012692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bone and bone related biochemical examinations. Hormone and hormone related substances. Parathyroid hormone].
    Tanaka M; Fukagawa M
    Clin Calcium; 2006 Jun; 16(6):927-34. PubMed ID: 16751687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone.
    Iwasaki-Ishizuka Y; Yamato H; Nii-Kono T; Kurokawa K; Fukagawa M
    Nephrol Dial Transplant; 2005 Sep; 20(9):1904-11. PubMed ID: 15985520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Low PTH level and adynamic bone disease in dialysis patients].
    Shiizaki K; Sumikado S; Akizawa T
    Clin Calcium; 2004 Jan; 14(1):16-20. PubMed ID: 15576948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of intact PTH by isolated perfused kidney and liver from uremic rats.
    Daugaard H; Egfjord M; Lewin E; Olgaard K
    Exp Nephrol; 1994; 2(4):240-8. PubMed ID: 8069660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use and indication of vitamin D and vitamin D analogues in patients with renal bone disease].
    Malluche HH; Kubodera N
    Clin Calcium; 2002 Jun; 12(6):724-9. PubMed ID: 15775357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular immunity and levels of parathyroid hormone in uremic patients receiving hemodialysis.
    Griveas I; Visvardis G; Papadopoulou D; Mitsopoulos E; Kyriklidou P; Manou E; Meimaridou D; Ginikopoulou E; Sakellariou G; Fleva A; Zilidou R; Paulitou A
    Ren Fail; 2005; 27(3):275-8. PubMed ID: 15957542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Resistance to the calcemic action of parathyroid hormone in chronic renal failure].
    Miyamoto K; Ito M; Kuwahata M
    Clin Calcium; 2001 Aug; 11(8):1014-8. PubMed ID: 15775608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insufficiency of PTH action on bone in uremia.
    Iwasaki Y; Yamato H; Nii-Kono T; Fujieda A; Uchida M; Hosokawa A; Motojima M; Fukagawa M
    Kidney Int Suppl; 2006 Jul; (102):S34-6. PubMed ID: 16810309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there an optimal parathyroid hormone level in end-stage renal failure: the lower the better?
    Sakhaee K
    Curr Opin Nephrol Hypertens; 2001 May; 10(3):421-7. PubMed ID: 11342808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The opposing actions of the two parathyroid hormones, 1-84 PTH and 7-84 PTH: improvement in renal bone and calcium metabolism management.
    Cantor TL
    Hemodial Int; 2004 Oct; 8(4):372-85. PubMed ID: 19379445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Australian Endocrine Surgeons Guidelines AES06/01. Postoperative parathyroid hormone measurement and early discharge after total thyroidectomy: analysis of Australian data and management recommendations.
    AES Guidelines 06/01 Group
    ANZ J Surg; 2007 Apr; 77(4):199-202. PubMed ID: 17388819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overproduction and secretion of a novel amino-terminal form of parathyroid hormone from a severe type of parathyroid hyperplasia in uremia.
    Arakawa T; D'Amour P; Rousseau L; Brossard JH; Sakai M; Kasumoto H; Igaki N; Goto T; Cantor T; Fukagawa M
    Clin J Am Soc Nephrol; 2006 May; 1(3):525-31. PubMed ID: 17699255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.